Rodman & Renshaw analyst Michael King Jr. initiates coverage on Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) with a Buy rating and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE